SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality—a secondary analysis of the ACTIV-1 trial DOI Creative Commons
Alfredo J Mena Lora,

Kimberly Enders,

Huimin Wu

et al.

Therapeutic Advances in Infectious Disease, Journal Year: 2025, Volume and Issue: 12

Published: April 1, 2025

Background: Understanding factors that predict progression to severe COVID-19 is critical. Antibodies targeting SARS-CoV-2 spike protein confer protection, while the N of plays roles in viral replication and immune dysfunction. This study explores significance anti-spike antibodies on disease severity, progression, mortality. Objectives: To evaluate relationship between antibody levels with clinical outcomes, mortality hospitalized patients COVID-19. Design: A secondary analysis serologic data from participants ACTIV-1 randomized trial, which evaluated immunomodulators for treatment Methods: subanalysis modulator trial was conducted. Samples collected at randomization were tested antibodies. Logistic regression linear models employed examine association serological measures including 28-day as well high-flow nasal cannula (HFNC) invasive mechanical ventilation (MV). Results: Among 496 detectable serum protein, median 1143 ng/dL, decreased 2559 ng/dL 6 days symptom onset 477.6 11 days. Higher seen progressed or severity increased. Greater associated mortality, prolonged oxygenation, ventilation, hospitalization, risk new non-invasive HFNC, MV, extracorporeal membrane oxygenation use. a higher HFNC use, longer duration, extended hospitalization. Anti-spike serologies not outcomes. Conclusion: could provide insights into prognosis. Further research needed explore implications these findings optimize patient care enhance

Language: Английский

SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality—a secondary analysis of the ACTIV-1 trial DOI Creative Commons
Alfredo J Mena Lora,

Kimberly Enders,

Huimin Wu

et al.

Therapeutic Advances in Infectious Disease, Journal Year: 2025, Volume and Issue: 12

Published: April 1, 2025

Background: Understanding factors that predict progression to severe COVID-19 is critical. Antibodies targeting SARS-CoV-2 spike protein confer protection, while the N of plays roles in viral replication and immune dysfunction. This study explores significance anti-spike antibodies on disease severity, progression, mortality. Objectives: To evaluate relationship between antibody levels with clinical outcomes, mortality hospitalized patients COVID-19. Design: A secondary analysis serologic data from participants ACTIV-1 randomized trial, which evaluated immunomodulators for treatment Methods: subanalysis modulator trial was conducted. Samples collected at randomization were tested antibodies. Logistic regression linear models employed examine association serological measures including 28-day as well high-flow nasal cannula (HFNC) invasive mechanical ventilation (MV). Results: Among 496 detectable serum protein, median 1143 ng/dL, decreased 2559 ng/dL 6 days symptom onset 477.6 11 days. Higher seen progressed or severity increased. Greater associated mortality, prolonged oxygenation, ventilation, hospitalization, risk new non-invasive HFNC, MV, extracorporeal membrane oxygenation use. a higher HFNC use, longer duration, extended hospitalization. Anti-spike serologies not outcomes. Conclusion: could provide insights into prognosis. Further research needed explore implications these findings optimize patient care enhance

Language: Английский

Citations

0